NCT00095069
Completed
Phase 3
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Groups Efficacy and Safety Extension Study of MK0928 in the Treatment of Adult Outpatients With Primary Insomnia
ConditionsInsomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Insomnia
- Sponsor
- H. Lundbeck A/S
- Enrollment
- 600
- Primary Endpoint
- Patient-reported amount of sleep and time to fall sleep at night after three months
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of insomnia
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Patient-reported amount of sleep and time to fall sleep at night after three months
Secondary Outcomes
- Functioning after 3 months
- Patient-reported awakenings at night
- Sleep quality
Similar Trials
Completed
Phase 3
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)InsomniaNCT00103818H. Lundbeck A/S900
Completed
Phase 3
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)InsomniaNCT00095043H. Lundbeck A/S320
Completed
Phase 3
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)InsomniaNCT00102167H. Lundbeck A/S663
Terminated
Phase 3
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)Primary InsomniaNCT00094666H. Lundbeck A/S465
Withdrawn
Phase 3
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)InsomniaNCT00102154H. Lundbeck A/S